OPTImize Price, MAXimize Access
Optimax Access is a UK-based Health Economics and Outcome Research (HEOR) consultancy company based in the United Kingdom, with an office in the Netherlands as well. We assist our clients in introducing their pharmaceutical and biotech products, and services to major global healthcare markets. We will help you to identify a clear and optimal pathway to success with a comprehensive catalog of services ranging from clinical study design to reimbursement assessment, health economics evidence generation and health technology assessment dossier submission.
What Make Us Special?
Lorem ipsum dolor sit amet, consectetur adipisc ing elit.
TEAM MEMBERS
A blend of experience from consultancy, industry and academia
Dr Amir Ansaripour
 HEOR Director
Amir is a pharmacist and health economist. He has collaborated with most of the top pharma companies by developing cost-effectiveness models for new products for various diseases.
His Ph.D. research focused on cost-effectiveness analyses, modeling, and reimbursement policy analysis. During the past years, he has applied various methods such as questionnaire/survey analysis, Matching-adjusted indirect comparisons (MAICs), data mining on a large claims database, real-world cost analysis, Markov modeling, pharmaceutical pricing, and market access strategy in his projects.
Dr Mehdi Javanbakht
Chief Executive Officer
Mehdi holds a Ph.D. in Health Economics and previously served as an Evidence Review Group member for NICE. He brings nearly 20 years of experience in health economics and health technology assessment. He has led and supported more than 250 health economics and outcomes research projects, contributing to the successful launch of many pharmaceutical and medtech products. His work has led to over 150 publications in peer-reviewed journals, and he is ranked among the top five most cited HTA specialists worldwide according to Google Scholar.
Mehdi has advised more than 300 biopharma and medtech companies and combines deep technical expertise in economic modeling with a strong commercial mindset.
Christoph S. Rommel
Non-Executive Director
Christoph brings over 40 years of international banking, governance, and investment experience. He has held senior leadership roles across Europe and Asia, including CEO & General Manager UK, Regional Head Asia Pacific, and CEO Singapore Branch for a leading German bank. As former Managing General Partner of Delbrück & Co Privatbankiers and now Partner at LANCEA LLP, Christoph supports Optimax Access with deep expertise in financial stewardship, corporate strategy, and fostering cross-border partnerships to drive sustainable international growth.
Michael Branagan-Harris
MedTech Market Access Strategy Principal Advisor
Michael began his career as a Royal Air Force paramedic, developing a strong focus on innovation and patient care. He entered the HealthTech sector in 1989, holding senior sales roles across the UK and Asia Pacific before becoming Managing Director of VNUS Medical Technologies UK. At VNUS, he led a value-based market access strategy with the introduction of VNUS Closure®, transforming varicose vein treatment and significantly reducing recovery times. The business grew to over $5M and was acquired by Covidien for $500m in 2009.
Michael later served as European Market Access & Reimbursement Director at Covidien before founding Device Access UK in 2010. Under his leadership, Device Access UK and Optimax Access UK supported more than 58 NICE approvals and numerous health economic publications. He exited Device Access in 2024.
Santoke Naal
Market Access Strategy Principal Consultant
Santoke has over 30 years of experience in the pharmaceutical industry, spanning senior commercial, policy, and market access roles. His career includes Managing Director at Pierre Fabre UK, oncology leadership at Novartis, and strategic policy negotiation at the ABPI, where he worked directly with government departments and senior NHS decision-makers. He has successfully overseen the launch of innovative medicines across oncology, rare diseases, and primary care.
Atefeh Mashayekhi
Head of Evidence Synthesis Team
Atefeh is the head of the Evidence Synthesis team at Optimax Access, she worked as an Evidence Synthesis Analyst at NIHR Innovation Observatory for several years. She has a strong background in health economics and Evidence Synthesis and has successfully managed several systematic review projects as part of NICE HTA submissions for pharmaceutical and medical devices companies. She has also published several Cochrane systematic reviews.
Eoin Moloney
HEOR Manager
Eoin (MSc) is a senior health economist and evidence synthesis specialist, with 10 years of experience in academia and industry. He has worked across a wide range of clinical disease areas, focussing on the cost-effectiveness and budget-impact of a variety of medical and pharmaceutical interventions. He has a strong track record of publications in high-impact clinical and economic journals and an in-depth understanding of the methods required to demonstrate the cost-effectiveness of new technologies.
Â
Melissa Gomez Montero
Senior Consultant
Melissa is a seasoned professional in Health Economics and Outcomes Research (HEOR), with extensive experience supporting pharmaceutical, biotech, and MedTech companies. She specializes in developing and adapting econaomic models, managing complex projects, and authoring scientific publications. Melissa holds an MSc in Health Economics from Erasmus University Rotterdam. After working at Cytel, she joined Optimax Access in May 2024, contributing to high-impact HEOR projects and publications. She is proficient in project management, statistical analysis, economic evaluation, and fluent in English, Spanish, French, and Portuguese.
Gamze Fackelmann
Marketing & Business Development Manager
Gamze is a marketing and business development expert with a strong background in pharmaceutical and medical industry. Holding a BSc in Molecular Biology and Genetics from ITU, an MBA with a marketing focus from ESSCA and ITU, and an MSc in Cancer Biology from UZH in Switzerland, Gamze combines scientific knowledge with business acumen. With a successful track record at renowned companies such as Pfizer and Novo Nordisk, she excels in formulating business development strategies, and executing marketing and sales campaigns.
 Victoria Zaitceva
Consultant
Victoria is a Health Economics Analyst with a PharmD and an MSc in International Health Policy from the London School of Economics, complemented by additional training in biostatistics. She brings a multidisciplinary background with experience spanning research, the pharmaceutical industry, and IT product development. Victoria is particularly passionate about leveraging coding languages to develop cost-effectiveness models that are both interactive and user-friendly.
Dr Elisabeth Brock
Scientific advisor (Market Access/ HEOR/ HTA specialist)
Elisabeth has more than 20 years of experience in supporting market access and HEOR functions at local, regional and global level with specialized strategic advice, as well as operational support. Elisabeth has been directly responsible for reimbursement submissions in Germany, Switzerland and the UK (NICE) and speaks German, French and Italian. Elisabeth has worked as a Principal at IQVIA’s Value and Payer Evidence function and in various positions at HealthEcon, an IGES Group company.
Professor Maziar Moradi-Lakeh
Head of Clinical Research Team
Maziar is a Medical Doctor with post-graduate studies in health metric and evaluation. He has been a consultant for several international organizations, governments, and companies. Maziar has contributed to publishing more than 180 papers in peer-reviewed journals.
OUR NETWORK
Have Questions?
Please complete the form below to contact us for more information
